Insulet Co. (NASDAQ:PODD) Shares Bought by Scholtz & Company LLC

Scholtz & Company LLC grew its position in Insulet Co. (NASDAQ:PODD) by 8.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,080 shares of the medical instruments supplier’s stock after purchasing an additional 669 shares during the quarter. Insulet makes up 1.1% of Scholtz & Company LLC’s investment portfolio, making the stock its 28th largest position. Scholtz & Company LLC’s holdings in Insulet were worth $2,371,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Trexquant Investment LP lifted its position in shares of Insulet by 25.9% during the 4th quarter. Trexquant Investment LP now owns 68,045 shares of the medical instruments supplier’s stock worth $17,765,000 after buying an additional 13,996 shares during the last quarter. Geode Capital Management LLC raised its stake in Insulet by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock worth $463,347,000 after acquiring an additional 40,566 shares in the last quarter. National Bank of Canada FI lifted its position in Insulet by 148.7% in the fourth quarter. National Bank of Canada FI now owns 70,805 shares of the medical instruments supplier’s stock valued at $18,485,000 after acquiring an additional 42,337 shares during the last quarter. B. Metzler seel. Sohn & Co. AG lifted its stake in Insulet by 9.8% in the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 10,476 shares of the medical instruments supplier’s stock valued at $2,735,000 after buying an additional 934 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC increased its holdings in shares of Insulet by 43.7% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 5,291 shares of the medical instruments supplier’s stock valued at $1,381,000 after acquiring an additional 1,610 shares during the period.

Insulet Stock Up 0.2 %

PODD stock opened at $263.18 on Wednesday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company’s 50-day moving average price is $271.17 and its 200 day moving average price is $259.40. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a market cap of $18.48 billion, a P/E ratio of 45.45, a P/E/G ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Stifel Nicolaus raised their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Canaccord Genuity Group raised their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Raymond James reaffirmed an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.